Table 1.

Patient and tumor characteristics of the entire patient cohort.

Parameter		No.
Number of patients		100
Primary origin tumor	Lung	53
	Melanoma	18
	Breast	17
	Other	12
Histological type	Adenocarcinoma	66
	Melanoma	18
	Squamous Cell	7
	Other	9
Mutations *	Wild-Type	49
	PD-L1	29 (56.9%)
	EGFR	9 (17.6%)
	BRAF	8 (15.7%)
	HER2	6 (11.8%)
	ALK	3 (5.9%)
PS ECOG	0	33
	1	52
	2	12
	3	1
Median time from the diagnosis of the primary tumor to BM [range]		23 months [0–312]
Timing of BM	Synchronous	69
	Metachronous	31
Polymetastatic progression	Yes	40
	No	60
Pre-RT ST	Yes	70
	No	30
Pre-RT ST regimen **	Chemotherapy	25 (35.7%)
	Immunotherapy	26 (37.1%)
	Targeted therapy	15 (21.4%)
	Hormonal therapy	4 (5.7%)
No. of systemic line **	First-line	43 (61.4%)
	Second-line	18 (25.7%)
	Third-line or higher	9 (12.9%)

* Mutations were identified in 51 patients, with some patients having more than one category of mutation type. The percentages were reported based on this subset of 51 patients, rather than the entire 100-patient population. ** Pre-RT ST was prescribed in 70 patients. The percentages of the pre-RT ST regimen and systemic line number were reported based on this subset of 70 patients, rather than the entire 100-patient population. Abbreviations: PS ECOG = eastern cooperative oncology group performance status, ST = systemic therapy.